Soluble podoplanin as a biomarker in diffuse‑type gastric cancer

Takiguchi,Koichi; Shoda,Katsutoshi; Nakayama,Takashi; Takahashi,Kazunori; Saito,Ryo; Yamamoto,Atsushi; Furuya,Shinji; Akaike,Hidenori; Hosomura,Naohiro; Kawaguchi,Yoshihiko; Amemiya,Hidetake; Kawaida,Hiromichi; Inoue,Shingo; Kono,Hiroshi; Konishi,Hirotaka; Otsuji,Eigo; Ichikawa,Daisuke

doi:10.3892/or.2022.8262

Soluble podoplanin as a biomarker in diffuse‑type gastric cancer

Authors:
- Koichi Takiguchi
- Katsutoshi Shoda
- Takashi Nakayama
- Kazunori Takahashi
- Ryo Saito
- Atsushi Yamamoto
- Shinji Furuya
- Hidenori Akaike
- Naohiro Hosomura
- Yoshihiko Kawaguchi
- Hidetake Amemiya
- Hiromichi Kawaida
- Shingo Inoue
- Hiroshi Kono
- Hirotaka Konishi
- Eigo Otsuji
- Daisuke Ichikawa
View Affiliations

Affiliations: First Department of Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi 409‑3898, Japan, Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto 602‑8566, Japan
Published online on: January 12, 2022 https://doi.org/10.3892/or.2022.8262
Article Number: 51

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diffuse‑type gastric cancer, also known as scirrhous gastric cancer, is characterized by a larger number of stromal cells, referred to as cancer‑associated fibroblasts (CAFs), than the number of cancer cells in the tissue. The present study focused on CAFs in gastric cancer and examined their potential as a blood biomarker. A total of 46 and 84 patients with gastric cancer were respectively included in a development and an independent validation cohort to assess the clinicopathological characteristics of plasma podoplanin (PDPN) levels. The prognostic impact of plasma PDPN was also investigated in the validation cohort. The cut‑off value of the plasma‑PDPN concentration was set to the median plasma PDPN concentration in the development cohort that was then divided into the high‑PDPN and low‑PDPN groups. The high‑PDPN group tended to have more diffuse‑type disease (P=0.079), which was further confirmed through logistic regression analysis (P=0.008). Kaplan‑Meier survival estimates indicated that the recurrence‑free survival rate was significantly lower in the high‑PDPN group (P=0.029). In conclusion, plasma soluble PDPN was demonstrated to be a marker for diffuse gastric cancer and may reflect the prognosis of this disease.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Izumi D, Zhu Z, Chen Y, Toden S, Huo X, Kanda M, Ishimoto T, Gu D, Tan M, Kodera Y, et al: Assessment of the diagnostic efficiency of a liquid biopsy assay for early detection of gastric cancer. JAMA Netw Open. 4:e21211292021. View Article : Google Scholar : PubMed/NCBI
3	Shoda K, Ichikawa D, Fujita Y, Masuda K, Hiramoto H, Hamada J, Arita T, Konishi H, Kosuga T, Komatsu S, et al: Clinical utility of circulating cell-free Epstein-Barr virus DNA in patients with gastric cancer. Oncotarget. 8:28796–28804. 2017. View Article : Google Scholar : PubMed/NCBI
4	Shoda K, Ichikawa D, Fujita Y, Masuda K, Hiramoto H, Hamada J, Arita T, Konishi H, Komatsu S, Shiozaki A, et al: Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer. Gastric Cancer. 20:126–135. 2017. View Article : Google Scholar : PubMed/NCBI
5	Miki Y, Yashiro M, Moyano-Galceran L, Sugimoto A, Ohira M and Lehti K: Crosstalk between cancer associated fibroblasts and cancer cells in scirrhous type gastric cancer. Front Oncol. 10:5685572020. View Article : Google Scholar : PubMed/NCBI
6	Huang KH, Chen MH, Fang WL, Lin CH, Chao Y, Lo SS, Li AF, Wu CW and Shyr YM: The clinicopathological characteristics and genetic alterations of signet-ring cell carcinoma in gastric cancer. Cancers (Basel). 12:23182020. View Article : Google Scholar : PubMed/NCBI
7	Shi H, Qi C, Meng L, Yao H, Jiang C, Fan M, Zhang Q, Hou X and Lin R: Bone marrow-derived mesenchymal stem cells promote Helicobacter pylori-associated gastric cancer progression by secreting thrombospondin-2. Cell Prolif. 54:e131142021. View Article : Google Scholar : PubMed/NCBI
8	Jeong HY, Ham IH, Lee SH, Ryu D, Son SY, Han SU, Kim TM and Hur H: Spatially distinct reprogramming of the tumor microenvironment based on tumor invasion in diffuse-type gastric cancers. Clin Cancer Res. 27:6529–6542. 2021. View Article : Google Scholar : PubMed/NCBI
9	Venning FA, Zornhagen KW, Wullkopf L, Sjölund J, Rodriguez-Cupello C, Kjellman P, Morsing M, Hajkarim MC, Won KJ, Erler JT and Madsen CD: Deciphering the temporal heterogeneity of cancer-associated fibroblast subpopulations in breast cancer. J Exp Clin Cancer. 40:1752021. View Article : Google Scholar : PubMed/NCBI
10	Nurmik M, Ullmann P, Rodriguez F, Haan S and Letellier E: In search of definitions: Cancer-associated fibroblasts and their markers. Int J Cancer. 146:895–905. 2020. View Article : Google Scholar : PubMed/NCBI
11	Maruyama S, Furuya S, Shiraishi K, Shimizu H, Akaike H, Hosomura N, Kawaguchi Y, Amemiya H, Kawaida H, Sudo M, et al: Podoplanin expression as a prognostic factor in gastric cancer. Anticancer Res. 38:2717–2722. 2018.PubMed/NCBI
12	Brierley JD, Gospodarowicz MK and Wittekind C: TNM classification of malignant tumours. 8th ed. John Wiley & Sons, Ltd.; 2017
13	Tomita H, Ichikawa D, Ikoma D, Sai S, Tani N, Ikoma H, Fujiwara H, Kikuchi S, Okamoto K, Ochiai T and Otsuji E: Quantification of circulating plasma DNA fragments as tumor markers in patients with esophageal cancer. Anticancer Res. 27:2737–2741. 2007.PubMed/NCBI
14	Lauren P: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 64:31–49. 1965. View Article : Google Scholar : PubMed/NCBI
15	Chen Y, Zhou Q, Wang H, Zhuo W, Ding Y, Lu J, Wu G, Xu N and Teng L: Predicting peritoneal dissemination of gastric cancer in the Era of precision medicine: Molecular characterization and biomarkers. Cancers (Basel). 12:22362020. View Article : Google Scholar : PubMed/NCBI
16	Kasashima H, Yashiro M, Nakamae H, Kitayama K, Masuda G, Kinoshita H, Fukuoka T, Hasegawa T, Nakane T, Hino M, et al: CXCL1-Chemokine (C-X-C Motif) receptor 2 signaling stimulates the recruitment of bone marrow-derived mesenchymal cells into diffuse-type gastric cancer stroma. Am J Pathol. 186:3028–3039. 2016. View Article : Google Scholar : PubMed/NCBI
17	Liu X, Cao Y, Lv K, Gu Y, Jin K, He X, Fang H, Fei Y, Shi M, Lin C, et al: Tumor-infiltrating podoplanin⁺ cells in gastric cancer: Clinical outcomes and association with immune contexture. Oncoimmunology. 9:18450382020. View Article : Google Scholar : PubMed/NCBI
18	Cimini M and Kishore R: Role of podoplanin-positive cells in cardiac fibrosis and angiogenesis after ischemia. Front Physiol. 12:6672782021. View Article : Google Scholar : PubMed/NCBI
19	Suzuki-Inoue K: Platelets and cancer-associated thrombosis: Focusing on the platelet activation receptor CLEC-2 and podoplanin. Blood. 134:1912–1918. 2019. View Article : Google Scholar : PubMed/NCBI
20	Quintanilla M, Montero-Montero L, Renart J and Martín-Villar E: Podoplanin in Inflammation and Cancer. Int J Mol Sci. 20:7072019. View Article : Google Scholar : PubMed/NCBI
21	Sugai T, Uesugi N, Kitada Y, Yamada N, Osakabe M, Eizuka M, Sugimoto R, Fujita Y, Kawasaki K, Yamamoto E, et al: Analysis of the expression of cancer-associated fibroblast- and EMT-related proteins in submucosal invasive colorectal cancer. J Cancer. 9:2702–2712. 2018. View Article : Google Scholar : PubMed/NCBI
22	Neri S, Ishii G, Hashimoto H, Kuwata T, Nagai K, Date H and Ochiai A: Podoplanin-expressing cancer-associated fibroblasts lead and enhance the local invasion of cancer cells in lung adenocarcinoma. Int J Cancer. 137:784–796. 2015. View Article : Google Scholar : PubMed/NCBI
23	Zhao X, Pan Y, Ren W, Shen F, Xu M, Yu M, Fu J, Xia L, Ruan C and Zhao Y: Plasma soluble podoplanin is a novel marker for the diagnosis of tumor occurrence and metastasis. Cancer Sci. 109:403–411. 2018. View Article : Google Scholar : PubMed/NCBI
24	Kemi N, Eskuri M, Herva A, Leppänen J, Huhta H, Helminen O, Saarnio J, Karttunen TJ and Kauppila JH: Tumour-stroma ratio and prognosis in gastric adenocarcinoma. Br J Cancer. 119:435–439. 2018. View Article : Google Scholar : PubMed/NCBI
25	Suzuki-Inoue K, Inoue O, Ding G, Nishimura S, Hokamura K, Eto K, Kashiwagi H, Tomiyama Y, Yatomi Y, Umemura K, et al: Essential in vivo roles of the C-type lectin receptor CLEC-2: Embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. J Biol Chem. 285:24494–24507. 2010. View Article : Google Scholar : PubMed/NCBI
26	Suzuki-Inoue K: Roles of the CLEC-2-podoplanin interaction in tumor progression. Platelets. 1–7. 2018.(Epub ahead of print). PubMed/NCBI
27	Carrasco-Ramírez P, Greening DW, Andrés G, Gopal SK, Martín-Villar E, Renart J, Simpson RJ and Quintanilla M: Podoplanin is a component of extracellular vesicles that reprograms cell-derived exosomal proteins and modulates lymphatic vessel formation. Oncotarget. 7:16070–16089. 2016. View Article : Google Scholar : PubMed/NCBI